Clonazepam for Refractory Headache: Three Cases Illustrative of Benefit and Risk

Morris Maizels, MD

Disclosures

Headache. 2010;50(4):650-656. 

In This Article

Conclusion

There have been no adequate scientific studies of the role of benzodiazepines in the prophylaxis of migraine or other primary headache disorders. Although open-label studies of clonazepam for chronic pain disorders have suggested a possible role, there is as yet insufficient evidence to support such a role. Further, to whatever extent benzodiazepines may ameliorate the pain experience, they may do so by reducing the emotional responses to pain. A case series of 3 patients with various primary headache disorders associated with some component of anxiety, insomnia, or somatoform symptoms is presented. These patients illustrate potential benefits as well as harm from the use of clonazepam. We suggest, while awaiting adequate scientific study, that clonazepam may be considered for the patient with headache refractory to standard therapies, with comorbid anxiety, insomnia, or somatoform symptoms, after adequate psychiatric evaluation has been performed, and with careful monitoring of drug use and outcomes.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....